In the Original Investigation titled “Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program,”1 published online May 13, 2019, there were errors in the caption to Figure 2. The last 2 sentences should read as follows: “The dotted line corresponds to the 1-year return threshold (HPV-positive negative for intraepithelial lesions or malignant neoplasm [NILM], 2.8%), and the dashed line corresponds to the colposcopy referral threshold (HPV-positive atypical squamous cells of undetermined significance [ASC-US], 5.7%). FDA indicates US Food and Drug Administration.” This article was corrected online. This article was also corrected on June 10, 2019, to add Open Access.
1.Wentzensen
N, Clarke
MA, Bremer
R,
et al. Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program [published online May 13, 2019].
JAMA Intern Med. doi:
10.1001/jamainternmed.2019.0306PubMedGoogle Scholar